FOXA1 and prostate cancer: We observed active enhancer regions (H3K27ac) in the castration-resistant setting, co-occupied by AR and FOXA1, at the amplified AR-enhancer. This is substantially stronger when compared to the hormone-sensitive primary prostate cancer samples without somatic amplifications (Fig. 4c and Supplementary Fig. 7).